Annabel Samimy
Stock Analyst at Stifel
(3.41)
# 963
Out of 4,910 analysts
54
Total ratings
43.75%
Success rate
26.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $45 | $38.63 | +16.49% | 1 | Mar 26, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $18.27 | +173.67% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $4.11 | +337.96% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $3.39 | +401.49% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $13.03 | +207.10% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $7.79 | +131.07% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $9.05 | +165.19% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $9.13 | +338.12% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $33.50 | +138.81% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $118.01 | +94.90% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $9.64 | +159.47% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.81 | +96.52% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $20.09 | +223.54% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $7.23 | +3,703.60% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $14.26 | +215.57% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $0.54 | +1,384.78% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.50 | +4,686.60% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.14 | +65,689.47% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $32.85 | -26.94% | 7 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $21 | $0.59 | +3,473.86% | 6 | Sep 18, 2019 |
Palvella Therapeutics
Mar 26, 2025
Initiates: Buy
Price Target: $45
Current: $38.63
Upside: +16.49%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $18.27
Upside: +173.67%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $4.11
Upside: +337.96%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $3.39
Upside: +401.49%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $13.03
Upside: +207.10%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.79
Upside: +131.07%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $9.05
Upside: +165.19%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $9.13
Upside: +338.12%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $33.50
Upside: +138.81%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $118.01
Upside: +94.90%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $9.64
Upside: +159.47%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $17.81
Upside: +96.52%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $20.09
Upside: +223.54%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $7.23
Upside: +3,703.60%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $14.26
Upside: +215.57%
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $0.54
Upside: +1,384.78%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.50
Upside: +4,686.60%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.14
Upside: +65,689.47%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $32.85
Upside: -26.94%
Sep 18, 2019
Maintains: Hold
Price Target: $15 → $21
Current: $0.59
Upside: +3,473.86%